Slowly Digestible Carbohydrates for GLP-1 Secretion

May 1, 2026 updated by: Bruce R. Hamaker, Purdue University

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.

Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.

There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:

  • Consume a randomized test beverage (SDC or maltodextrin)
  • Receive a blood draw at 7 timepoints over 3 hrs
  • Take a satiety questionnaire 5 times over 3 hrs
  • Consume a standardized lunch 3 hrs after the test beverage consumption

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Indiana
      • West Lafayette, Indiana, United States, 47907
        • Recruiting
        • Clinical Research Center at Purdue University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy population
  2. BMI between 18.5 and 24.9 kg/m2
  3. Adults 18 - 45 years old
  4. Men or women
  5. Able to read/speak English
  6. Fasting blood glucose levels ≤100 mg/dL
  7. HbA1c ≤ 5.7%

Exclusion Criteria:

  1. Participants with 18 > Years of Age > 45 will be excluded.
  2. Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
  3. Diabetic individuals will be excluded.
  4. Individuals with history of gastrointestinal disease will be excluded from the study.
  5. Pregnant or nursing women will also be excluded.
  6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
  7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Maltodextrin
Maltodextrin increases GLP-1 from 0-60 minutes but doesn't have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume a treatment that is either entirely maltodextrin or partially maltodextrin during each of the 4 study visits.
Dietary supplement: Maltodextrin (Placebo)
75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit
Other Names:
  • Control
Experimental: Low-Dose SDC
20 g of raw corn starch (SDC) + 55g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the low-dose once during one of the study visits.
Dietary supplement: Maltodextrin (Placebo)
75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit
Other Names:
  • Control
Dietary supplement: Raw Corn Starch
Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).
Other Names:
  • Slowly-Digestible Carbohydrate
  • Ileal-Digesting Starch
Experimental: Medium-Dose SDC
40 g of raw corn starch (SDC) + 35g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the medium-dose once during one of the study visits.
Dietary supplement: Maltodextrin (Placebo)
75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit
Other Names:
  • Control
Dietary supplement: Raw Corn Starch
Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).
Other Names:
  • Slowly-Digestible Carbohydrate
  • Ileal-Digesting Starch
Experimental: High-Dose SDC
60 g of raw corn starch (SDC) + 15g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the high-dose once during one of the study visits.
Dietary supplement: Maltodextrin (Placebo)
75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit
Other Names:
  • Control
Dietary supplement: Raw Corn Starch
Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).
Other Names:
  • Slowly-Digestible Carbohydrate
  • Ileal-Digesting Starch

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total GLP-1 Secretion
Time Frame: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma GLP-1 concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma and ELISA Total GLP-1 Kits.
From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satiety
Time Frame: From baseline, 60, 120, 180 minutes and after a second meal for each participant over the course of the 4 arms.
Measure satiety at baseline, 60, 120, 180 minutes and after a second meal via satiety questionnaires
From baseline, 60, 120, 180 minutes and after a second meal for each participant over the course of the 4 arms.
Blood Glucose
Time Frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma glucose concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood serum.
From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
Insulin
Time Frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on insulin concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma.
From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Purdue University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

November 25, 2026

Study Registration Dates

First Submitted

May 1, 2026

First Submitted That Met QC Criteria

May 1, 2026

First Posted (Actual)

May 7, 2026

Study Record Updates

Last Update Posted (Actual)

May 7, 2026

Last Update Submitted That Met QC Criteria

May 1, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-2025-00000283

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Glucose

Clinical Trials on Maltodextrin (Placebo)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe